NewGenIvf Group Limited (NIVF) P/E Ratio History
Deep ValueTrading at 0.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2024–2024
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, NewGenIvf Group Limited (NIVF) trades at a price-to-earnings ratio of 0.0x, with a stock price of $1.31 and trailing twelve-month earnings per share of $-2.35.
The current P/E is 100% below its 5-year average of 236.2x. Over the past five years, NIVF's P/E has ranged from a low of 236.2x to a high of 236.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, NIVF trades at a 100% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
Relative to the broader market, NIVF trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NIVF DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NIVF Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
NIVF P/E vs Peers
Healthcare Providers (Non-Insurers) peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 47.4 | 7.07 | +14% | |
| $7B | 9.2Lowest | 0.28Best | -6% | |
| $8B | 70.9 | - | -4% | |
| $29B | 35.2 | 8.32 | +171%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
NIVF Historical P/E Data (2024–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | - | $72900.00 | $308.61 | 236.2x | +0% |
Average P/E for displayed period: 236.2x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NIVF — Frequently Asked Questions
Quick answers to the most common questions about buying NIVF stock.
What is NIVF's P/E ratio?
NewGenIvf Group Limited (NIVF) trailing twelve-month P/E ratio is 0.0x, based on TTM diluted EPS of $-2.35. The 5-year average P/E is 236.2x and the historical range spans 236.2x to 236.2x.
Is NIVF stock overvalued or undervalued?
NIVF current P/E: 0.0x. 5-year average P/E: 236.2x. Percentile: 0th.
Is NIVF stock expensive?
NIVF is fairly valued relative to its own history. The current P/E of 0.0x is near the 5-year average of 236.2x (0th percentile of historical range).
What is NIVF's historical P/E range?
Over the past 5 years, NIVF's P/E ratio has ranged from 236.2x to 236.2x, with a median of 236.2x and an average of 236.2x. The current P/E of 0.0x places the stock at the 0th percentile of this range. Full historical data spans 2024–2024.
How does NIVF's P/E compare to the S&P 500?
NIVF current P/E: 0.0x. S&P 500 median P/E: 25.9x.
How does NIVF's valuation compare to Healthcare peers?
NewGenIvf Group Limited P/E of 0.0x can be benchmarked against Healthcare peers in the comparison table on this page.
What is NIVF's PEG ratio?
NIVF PEG ratio is N/A, based on a P/E of 0.0x and EPS growth of 175.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is NIVF's earnings yield?
NIVF earnings yield is 100.00%, the inverse of its 0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.